Somatropin pegylated - GeneScience Pharmaceuticals

Drug Profile

Somatropin pegylated - GeneScience Pharmaceuticals

Alternative Names: GenSci-004; JINTOPIN AQ; Jintrolong®; Jintropin; Jintropin AQ; PEG-rhGH - GeneScience Pharmaceuticals; PEG-somatropin; Recombinant human growth hormone - GeneScience Pharmaceuticals

Latest Information Update: 20 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GeneScience Pharmaceuticals
  • Developer First Hospital of Jilin University; GeneScience Pharmaceuticals; Nanjing Medical University; Shanghai Jiao Tong University; Zhejiang University
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Somatotropin deficiency
  • Phase III Prader-Willi syndrome; Short stature
  • Phase II Turner's syndrome

Most Recent Events

  • 01 May 2018 GeneScience Pharmaceuticals initiates enrolment in a phase III trial for Short stature in China (NCT03535415)
  • 14 Apr 2018 Phase-III clinical trials in Prader-Willi syndrome (In infants, In children) in China (SC) (NCT03554031)
  • 31 Mar 2017 Phase-II clinical trials in Somatotropin deficiency (In adults) in China (SC) (NCT03104010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top